Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation
Conditions: Liver Transplant; Complications; Hepatocarcinoma; Recurrent Osteosarcoma; High-Risk Cancer Intervention: Drug: multi-kinase inhibitors in combination with bevacizumab Sponsor: Peking Union Medical College Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Avastin | Bone Cancers | Cancer | Cancer & Oncology | Carcinoma | Hepatocellular Carcinoma | Hospitals | Liver | Liver Cancer | Liver Transplant | Osteosarcoma | Research | Transplant Surgery | Transplants | Urology & Nephrology